Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ambrisenttan in patients with severe COVID-19
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: NOORIK BIOPHARMACEUTICALS AG
- Phase: II
- Execution start: 26/02/2021
- End of execution: 30/10/2021
- IP: JOSE HERNANDEZ QUERO